35524-50-6

Upstream product

• 35524-48-2 1-(4-methylphenyl)pyrrole-2-carbonitrile 
• 30186-38-0 1-(4-methylphenyl)-2-formyl-1H-pyrrole 
• 106-49-0 p-toluidine 
• 827-60-1 1-(4-methylphenyl)-1H-pyrrole 
• 124-38-9 carbon dioxide 

Downstream Products

• 35524-53-9 1-p-tolyl-pyrrole-2-carbonyl chloride 
• 144062-62-4 1-(4-methylphenyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 144062-63-5 methyl 1-<4-(bromomethyl)phenyl>-1H-pyrrole-2-carboxylate 
• 144062-64-6 methyl 1-<4-<(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl>phenyl>-1H-pyrrole-2-carboxylate 
• 145062-02-8 methyl 1-<4-<<2-n-butyl-4-(hydroxymethyl)-5-chloroimidazolyl>methyl>phenyl>-1H-pyrrole-2-carboxylate 
• 145062-01-7 methyl 1-<4-<<2-n-butyl-4-chloro-5-(hydroxymethyl)imidazolyl>methyl>phenyl>-1H-pyrrole-2-carboxylate 

Relevant academic research and scientific papers

Efficient methods for optional metalation of 1-(methylphenyl)pyrroles in α or benzylic positions

Novel, selective metalation methods have been described for optional functionalisation of 1-(methylphenyl)pyrroles in α or benzylic positions and an efficient way for dilithiation of the model compounds has also been reported.

Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists

A series of 5-[1-[4-[(4,5-disubstituted-1H-imidazol-1-yl)methyl]- substituted]-1H-pyrrol-2-yl]-1H-tetrazoles and 5-[1-[4-[(3,5-dibutyl-1H- 1,2,4-triazol-1-yl)methyl]-substituted]-1H-pyrrol-2-yl]-1H-tetrazoles were investigated as novel AT1-sele

N-SUBSTITUTED (ALPHA-IMIDAZOLYL-TOLUYL) PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS

A class of N-substituted (α-imidazolyl-toluyl)pyrrole compounds described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula STR1 wherein m is one; wherein each of R 0 and R 1 is i

N-SUBSTITUTED N-(ALPHA-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS AND USE FOR TREATMENT OF CIRCULATORY DISORDERS

A class of N-substituted N-(α-triazolyltoluyl)pyrrole compounds described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula STR1 wherein m is one; wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R 2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R 3, R 4, R 5, R 6, R 7, R 8, R 9 and R. sup.10 is independently selected from hydrido, halo, nitro, trifluoromethyl, hydroxy, alkoxy, cyano, carboxyl and methoxycarbonyl; with the proviso that at least one of R 5 and R 8 must be selected from COOH, SH, PO 3 H 2, SO 3 H, CONHNH 2, CONHNHSO 2 CF 3, OH, STR2 wherein each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.